Bret Jensen

|RSS

Currently the editor of "The Biotech Forum," Bret Jensen was chief investment strategist for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami, from 2008-2011. The fund was in the top 5% of long/short hedge funds for total return in its first full year (2009), as ranked by Hedgeco fund database (more than 450 funds in category). Prior to this, he spent a decade as technology director of a Fortune 100 firm.Expand

Jensen has been a top-5%-ranked financial analyst and blogger since 2013, according to TipRanks. He holds a Bachelor of Science degree in finance from Arizona State University.

Follow Bret on Twitter: @Bret_Jensen.Collapse

By

Bret Jensen

 | Sep 25, 2017 | 4:10 PM EDT
Market ends down slightly across the board as it has been throughout the day. Only real damage was in the NASDAQ which was down some 1% on…
By

Bret Jensen

 | Sep 25, 2017 | 2:00 PM EDT
Not a whole of movement since our last update. All major indices remain down and technology is one of weakest parts of the market this Monday. The…
By

Bret Jensen

 | Sep 25, 2017 | 12:11 PM EDT
Noon update The market has taken a bit of downturn since our last update. All the major indices are sporting declines as we head towards midday.…
By

Bret Jensen

 | Sep 25, 2017 | 10:37 AM EDT
Not much in the way of trading action to begin the new week. All indices are down slightly an hour into trading this Monday. Individual names are…
RMPIA
By

Bret Jensen

 | Sep 25, 2017 | 8:45 AM EDT
We're less than an hour away from the opening of the new trading week as we close out September and the third quarter. Futures remain largely flat. …
By

Bret Jensen

 | Sep 25, 2017 | 7:04 AM EDT
Howdy, everyone. Hope all had a relaxing weekend. I am Bret Jensen, and I am happy to be standing in for Doug Kass here on the Daily Diary today and…
By

Bret Jensen

 | Sep 23, 2017 | 2:00 PM EDT
Winning FDA approval isn't always a win.
By

Bret Jensen

 | Sep 20, 2017 | 10:00 AM EDT
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
By

Bret Jensen

 | Sep 18, 2017 | 1:00 PM EDT
The two small-cap names appear undervalued at current trading levels.
By

Bret Jensen

 | Sep 15, 2017 | 12:00 PM EDT
Plus, what's going on with Lexicon Pharmaceuticals?

BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.